Key Points
- Insider Henry Pelish sold 3,093 shares on April 9 at an average price of $104.48 for $323,156.64, trimming his stake by 4.5% to 65,604 shares valued at about $6.85 million.
- Analysts are broadly positive with 16 Buys and 1 Sell, and a consensus rating of "Moderate Buy" with a $137.25 average target; notable recent targets include Cantor Fitzgerald $140 and Wedbush $125.
- NUVL has a market capitalization of $8.15 billion, a negative P/E (-17.72), a 52-week range of $63.56–$113.01, and 50/200-day moving averages near $101 and $100 respectively.
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Henry Pelish sold 3,093 shares of the stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the transaction, the insider directly owned 65,604 shares of the company's stock, valued at $6,854,305.92. The trade was a 4.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Nuvalent Stock Performance
NASDAQ:NUVL opened at $103.69 on Tuesday. The stock has a market capitalization of $8.15 billion, a P/E ratio of -17.72 and a beta of 1.31. Nuvalent, Inc. has a fifty-two week low of $63.56 and a fifty-two week high of $113.01. The company has a 50 day moving average price of $101.41 and a 200 day moving average price of $100.28.
Analyst Ratings Changes
A number of research firms have issued reports on NUVL. Wedbush reiterated an "outperform" rating and set a $125.00 target price on shares of Nuvalent in a report on Wednesday, April 8th. UBS Group reiterated a "buy" rating on shares of Nuvalent in a research note on Wednesday, December 17th. Wells Fargo & Company started coverage on shares of Nuvalent in a research note on Monday, March 30th. They set an "overweight" rating and a $116.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvalent in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald lifted their price target on shares of Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Friday, February 27th. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Nuvalent currently has a consensus rating of "Moderate Buy" and a consensus target price of $137.25.
Get Our Latest Research Report on Nuvalent
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company's stock worth $34,000 after purchasing an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Nuvalent during the third quarter worth about $38,000. Eastern Bank purchased a new stake in Nuvalent during the third quarter worth about $52,000. NBC Securities Inc. acquired a new position in Nuvalent during the fourth quarter worth about $125,000. Finally, KBC Group NV raised its position in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company's stock worth $154,000 after acquiring an additional 297 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.
Nuvalent Company Profile
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
